Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Denardo

Showing results (221-230 of 274) with videos related to

Pageof 28
Sort By:
Clinical Lymphoma|November 15, 2001
Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphomaG L DeNardo, S J DeNardo, R T O'Donnell, et al.
The American Journal of Cardiology|November 1, 1977
Problem of diffuse cardiac uptake of technetium-99m pyrophosphate in the diagnosis of acute myocardial infarction: enhanced scintigraphic accuracy by computerized selective blood pool subtractionD S Berman, E A Amsterdam, H H Hines, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparisonBarry W Wessels, Wesley E Bolch, Lionel G Bouchet, et al.
Annals of Internal Medicine|June 1, 1976
Prevention of lower extremity venous thrombosis by early mobilization. Confirmation in patients with acute myocardial infarction by 125I-fibrinogen uptake and venographyR R Miller, J E Lies, R F Carretta, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapyB R Leigh, P A Burke, A M Hong, et al.
Blood|January 4, 2003
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenograftsJoseph M Tuscano, Robert T O'Donnell, Laird A Miers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancerSally J DeNardo, Carol M Richman, Huguette Albrecht, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1987
Comparative serum stability of radiochelates for antibody radiopharmaceuticalsW C Cole, S J DeNardo, C F Meares, et al.
Cancer|December 24, 1997
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinomaS J DeNardo, L A Kroger, K R Lamborn, et al.
The International Journal of Biological Markers|January 1, 1987
Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodiesS J DeNardo, G L DeNardo, L F O'Grady, et al.
Pageof 28

Showing results (221-230 of 274) with videos related to

Sort By:
Pageof 28
Clinical Lymphoma|November 15, 2001
Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphomaG L DeNardo, S J DeNardo, R T O'Donnell, et al.
The American Journal of Cardiology|November 1, 1977
Problem of diffuse cardiac uptake of technetium-99m pyrophosphate in the diagnosis of acute myocardial infarction: enhanced scintigraphic accuracy by computerized selective blood pool subtractionD S Berman, E A Amsterdam, H H Hines, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparisonBarry W Wessels, Wesley E Bolch, Lionel G Bouchet, et al.
Annals of Internal Medicine|June 1, 1976
Prevention of lower extremity venous thrombosis by early mobilization. Confirmation in patients with acute myocardial infarction by 125I-fibrinogen uptake and venographyR R Miller, J E Lies, R F Carretta, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapyB R Leigh, P A Burke, A M Hong, et al.
Blood|January 4, 2003
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenograftsJoseph M Tuscano, Robert T O'Donnell, Laird A Miers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancerSally J DeNardo, Carol M Richman, Huguette Albrecht, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1987
Comparative serum stability of radiochelates for antibody radiopharmaceuticalsW C Cole, S J DeNardo, C F Meares, et al.
Cancer|December 24, 1997
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinomaS J DeNardo, L A Kroger, K R Lamborn, et al.
The International Journal of Biological Markers|January 1, 1987
Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodiesS J DeNardo, G L DeNardo, L F O'Grady, et al.
Pageof 28